Initially 5 mg 3x wkly by bolus or IV inj. Dose titration should be made so that doses are individualized between 2.5 & 15 mg. The dose may be increased in 2.5 or 5 mg increments no more frequently than every 4 wk to max dose of 15 mg 3x wkly. Administer Parsabiv into the venous line of the dialysis circuit at the end of haemodialysis treatment during rinse-back or IV after rinse-back.
Risk of hypocalcaemia. Measure serum Ca prior to treatment initiation, w/in 1 wk of initiation or dose adjustment & every 4 wk during treatment. Ventricular arrhythmia & QT prolongation secondary to hypocalcaemia. Patients w/ history of convulsion disorder or CHF. Risk of adynamic bone in patients w/ PTH <100 pg/mL. +ve for binding Abs in patients w/ SHPT. Co-administration w/ other medicinal products known to lower serum Ca. Pregnancy & lactation. Childn <18 yr. No specific study in patients w/ hepatic impairment was performed.
Increased risk of severe hypocalcaemia w/ medicinal products known to reduce serum Ca levels. Patients receiving Parsabiv should not be given cinacalcet.
Sign Out
